Isozid (Isoniazid)

Isoniazid is a pro‑drug that is activated by the bacterial KatG enzyme. The activated form blocks the synthesis of mycolic acids, which are essential components of the mycobacterial cell wall, leading to cell‑wall disruption and bacterial death.

The dose of Isozid is determined by the prescribing clinician based on the patient’s weight, age, disease severity, and renal or hepatic function. No fixed regimen is provided here; the prescriber sets the appropriate dosing schedule.

Isoniazid is classified as Pregnancy Category C, meaning it should be used only if the potential benefit justifies the potential risk to the fetus. Limited data are available for breastfeeding; the decision should be made by a healthcare professional.

Enquiries for Isozid can be submitted via the product page on gnhindia.com. Provide the required quantity and institutional credentials; GNH India will verify trade or procurement eligibility, then respond with pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Isoniazid is a first‑line agent with a unique mechanism targeting mycolic‑acid synthesis, whereas drugs like rifampicin inhibit RNA synthesis. Isoniazid is generally well‑tolerated but carries a higher risk of hepatotoxicity and neuropathy, which can be mitigated with pyridoxine supplementation.

Isozid injectable solution should be stored at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the vial in its original packaging until use to maintain sterility and potency.

Isozid is given intravenously by a healthcare professional. The solution is typically diluted in an appropriate compatible fluid and infused over a prescribed period, following aseptic technique and institutional protocols.

The most serious adverse reactions include severe hepatotoxicity, hypersensitivity reactions such as Stevens‑Johnson syndrome, drug‑induced lupus, and rare cases of anaphylaxis. Prompt monitoring of liver function and early recognition of skin or systemic reactions are essential.

Isozid is contraindicated in patients with known hypersensitivity to isoniazid or any component of the formulation. Caution is advised in individuals with pre‑existing liver disease, severe peripheral neuropathy, or those taking other hepatotoxic medications.